In 1967, LAURITZEN proposed a dynamic test to investigate placental steroidogenesis [7] . Intravenous injection of 50 mg dehydroepiandrosteronesulfate (DHEA-S) to pregnant women induced an increase of urinary estriol excretion; but with placental insufficiency this increase was absent or reduced. Since 1973therehave been several studies of the DHEA-S Loading Test (DLT) in which maternal plasma levels of estrogens were determined [l, 2, 3, 4, 5, 6, 8, 12, 13, 14] . After an intravenous injection of 50 mg of DHEA-S, Estrone (Ei) levels increase about threefold within two to four hours and return to baseline values eight to twelve hours later; Estradiol (E 2 ) levels increase two to fivefold within the first hour and return to initial values twelve hours later; unconjugated estriol (E 3 ) sometimes shows an increase of 50% between six and twelve hours after the injection [13] . An adequate method for interpreting the DLT in cUnicaTu.se has not yet been found. The accuracy of the plasmatic DLT to indicate fetal risk has not been proven with certainty. Nevertheless NAGEY and PUPKINS [9, 11] using a mathematical representation of a physiological model of the DHEA to estrogen conversion System, demonstrated the ability of DLT to indicate fetal jeopardy or/and placental insufficiency. Using a similar model, we have attempted to investigate the decrease of placental aromatization in intra-uterine fetal growth retardation. l Material and method A Single DLT was performed on each of 27 pregnant women at 32-42 weeks gestation. All the patients were under care from the beginning of pregnancy till delivery by the Obstetrical department of the University of Liege. There was no fetal or neonatal death in the study. An intravenous injection of 50 mg DHEA-S (Ro 6-6827/6: RÖCHE S. A./Basel) was given in a single bolus at eight o'clock in the mörning. A blood sample was collect-cd prior to the injection and at least flve samples in the following three hours, the first one no more t h an 30 minutes after the injection. Serum unconjugated E 2 was determined by radioimmunoassay after extraction with etherandeluation on sephadex LH-20 columns in a benzene-dichloromethanemethanol System (60v-30v-l Ov). The results were analyzed by fitting a mathematical representation of a Physiologie model of the DHEA-S to E 2 conversion System, using a Computer program. This model is a modification of NAGEY'S [9] . It allows the evaluation of the DHEA-S to E 2 conversion rate constant given the serum E 2 concentrations and the time intervals after injection. Details on biologicaJ facts and assumptions and on the mathematical development which lead to the establishment of the model are clearly explained in NAGEY'S publication. Briefly, DHEA-S to E 2 conversion rate constant is calculated by fitting the following equation to the DLT data from each patient:
Curriculum vitae
where: t = time interval (min) E 2 (t) = Estradiol concen trations at different times after injection (Moles/litre) E 2 (o) = Estradiol concentration before injection (Moles/litre) Qo = DHEA-S concentration change induced by the DHEA-S injection = quantity of DHEA-S injected divided by plasma volume (Moles/litre) a = rate constant of DHEA-S to non-E 2 clearance
2.00000-07
1.60000-07 =rate constant of DHEA-S to E 2 conversion (Min ""*) c = rate constant of E 2 clearance Estimation of parameters is based on the least squares method. Owingto the fact that the relation between E 2 and parameters is a non-linear one, the problem does not admit analytical Solutions; parameters have been evaluated in all cases, using a Computer program of function minimization based on the NELDER-MEAD simplex method [10] . Fig. l. shows an example of the course of E 2 levels given by the Computer when fitting the equation to the DLT data of a representative patient (n° 34). The constant b, which reflects placental aromatization activity, is the required parameter. To clarify the meaning of b, it can be said that it represents the proportion of exogenous DHEA-S which can be converted to E 2 by the placenta in one minute.
Results
Tab. I gives the results of the DLTs in the 27 patients divided into six groups according to maternal pathology or pregnancy complication and feto-placental outcome. Group I is the control group and comprises eight patients who had uneventful pregnancies and normally grown undistressed infants. Group II comprises three cases of premature labor without any fetal impairment. Group III contains six cases of various pathological situations at test time without any feto-placental complications. Group IV includes three post-term DLT. One fetus presented acute distress during labor. Group V is composed of six cases of intra-uterine fetal growth retardation (I.U.G.R.) in which birth weights were below the lOth percentile. Details on pregnancy complication is given in the table. Group VI is a case of sex4inked hydrocephaly.
Basal E 2 levels (ng/ml) and DHEA-S to E 2 conversion rate constant (min" 1 X l O"" 6 ) are written for each DLT. Tab. II presents the mean and ränge (after logarithmic transformation) of'basal E 2 values and of DHEA-S to E 2 conversion rate constants for the three main clinical groups: Control group (I); pathological pregnancy group without fetal impairment (III) and I.U.G.R. group (V). Statistical comparison between group I and III and between group I and V uses the non-parametric confidence interval method. Serum E 2 concentrations before precursor injection are significantly lower in both the pathological pregnancy group and the I.U.G.R. group. DHEA-S to E 2 conversion rate constants are not significantly reduced in group III but are markedly impaired in group V.
Comments
It seems probable that in the pathogenesis of fetal risk, äs found in intra-uterine growth retardation, the decrease of utero-placental perfusion is usually the first event to occur. This decrease of uteroplacental blood flow occurs in various disturbances of pregnancy but acquires clinical importance when leading to fetal distress. It can be presumed that the decrease of blood flow, when sufficient to induce poor fetal growth may also lead to a diminution of placental enzyme capacity. This diminution cannot be demonstrated by simple blood estrogen determination which may be reduced by a low availability of precursors. Many patients excrete little estrogen without lowered placental aromatization. It appears of first importance to evaluate the placental biosynthetic capacity äs an Information on fetal health.
The DHEA-S to E 2 conversion rate constant, such äs determined in this paper, reflects the speed of placental aromatization of C-19 precursors to estrogens. It may thus be considered äs a good index of placental enzyme capacity. It is shown that a low DHEA-S to E 2 conversion rate constant is more often associated with lowered fetal growth which cannot be indicated by simple basal E 2 determination. The low estrogen levels in fetal impairment do not result from a diminution of precursor availability alone but also from reduced placental enzyme capacity. This mathematical model is not applicable to serum unconjugated E 3 concentrations for two reasons. First, the E 3 rise after i.v. DHEA-S injection is not always significant and occurs more than four hours after the injection. Thus one of \the assumptions which lead to the establishment of the model is invalid in this case [9] . Secondly, E 3 production from C-19 precursors involves a 16-a hydroxylation which mainly occurs in the fetus or in the maternal liver. The physiological model considered simply äs a two compartments model is barely suffident to describe the E 2 change during the DLT. The model should certainly be inadequate for investigating three or more compartments äs for E 3 . As described in this paper, DLT u sing the calculation of the DHEA-S to E 2 conversion rate constant allows only a placental evaluation. But this evaluation is more sensitive because by administering DHEA-S the unknown variable "precursor" is excluded. We agree with LAURITZEN'S opinion [8] that the test is not a substitute for the usual estrogen determinations, but should rather be complementary to them and give additional information on the eventuai repercussions of the so called "placental insuffidency" on fetal wellbeing.
Summaiy
This study attempts to investigate the decreaseof placental aromatization of dehydroepiandrosterone-sulfate (DHEAr S) to estrogens, in case of fetal growth retardation. 27 intravenöus DHEA-S loading tests (DLT) have been performed in 27 pregnant women (Tab. I): There were eight normal pregnant women with normal babies (group I, control); six cases of various pathological situations without fetal impairment (group III), and six cases of intra-uterine fetal growth retardation (group V, I.U.G.R.)-Thedose of DHEA-S was 50 mg. The parameter investigated was the maternal serum concentration öf Estradiol (E 2 ) within the first three hours following the injection. The data were analyzed by f itting a mathematical representation of DHEA-S to £2 conversion System using a Computer program. This mathematical model permits the calculation of the DHEA-S to E 2 conversion rate constant, which represents the proportionof exogenous DHEA-S converted in £2 in one minute by the placenta and thus reflects the placental ability to aromatize €19 precursors. Table II presents the mean and ränge of E 2 baseline values and of DHEA-S to E 2 conversion rate constants for the three defined group s. Statisticalcomparisonshows that E 2 serum concentrations before the test are lower in both pathological group ( ) and IUGR group (V) whüe DHEA-S to E 2 conversion rate constant is impaired only in the IUGR group (V). It is concluded that fetal growth retardation, resulting from placental insufficiency, is more often associated with a lack of placental steroidosynthesis. The lowered estrogen excretion in case of fetal impairment does not result from a diminution of precursor availability alone but also from a reduced placental enzymatic capacity. The DLT and the calculation of DHEA-S to E 2 conversion rate constant is able to indicate the enzymatic insufficiency. It constitutes a sensitive test for evaluating placental disturbance.
Keywords: DHEA-S (loading test), estradiol metabolism, fetal growth retardation, placenta insufficiency, placenta metabolism. L'etude statistique montre queles taux de E 2 sont abaisses t an t dans les grossesses pathologiques (Groupe III) que dans les retards de croissance intra-uterine (groupe V I'U'G'R') tandis quela constante de conversion du DHEA-S en E 2 n'est diminuee que dans le cadre du retard de croissance (groupe V).
En conclusion, le retard de croissance resultant d'une insuffisance placentaire est bei et bien associe ä un defaut d'aromatisation placentaire qui contribue a expliquer en partie les taux circulant bas en oestrogenes.
Le test au DHEA-S et le calcul de la constante de conversion du DHEA-S en E 2 par la formule mathematique autorise une approche tres fine des troubles metaboliques placentaires.
Mots cles: Croissance foetale, DHEA-test, insuffisance placentaire, metabolisme placentaire, Oestradiol.
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